Table 1 Baseline characteristics.
From: Long-term treated HIV infection is associated with platelet mitochondrial dysfunction
PLHIV (n = 208) | Healthy controls (n = 56) | |
|---|---|---|
Sex (% Female) | 17 (8.2) | 22 (39.2)* |
Age (years, median [IQR]) | 52.0 [45.8, 59.0] | 30.0 [25.8–53.0]* |
BMI (median [IQR]) | 24.1 [22.0, 26.0] | 23.8 [21.5–25.6] |
HIV infection duration (years, median [IQR]) | 8.5 [5.0, 14.2] | |
Way of transmission (%) | ||
Heterosexual | 8 (3.8) | |
IDU | 3 (1.4) | |
MSM | 158 (76.0) | |
Other/unknown | 39 (18.8) | |
CD4 nadir (median [IQR]) | 250.0 [135.0, 362.5] | |
CD4 count (median [IQR]) | 660.0 [480.0, 812.5] | |
Undetectable HIV load, n (%) | 208 (100) | |
CD4/CD8 ratio (median [IQR]) | 0.8 [0.6, 1.1] | |
cART duration (years; median [IQR]) | 6.6 [4.1, 11.8] | |
cART regimen | ||
NRTI-use (%) | 200 (96.2) | |
NtRTI-use (%) | 97 (46.6) | |
NNRTI-use (%) | 61 (29.3) | |
PI-use (%) | 32 (15.4) | |
Maraviroc-use (%) | 3 (1.4) | |
INSTI-use (%) | 140 (67.3) | |
ABC (%) | 93 (44.7) | |
DTG (%) | 86 (41.3) | |
EVG (%) | 15 (7.2) | |
RAL (%) | 38 (18.3) | |
Smoking (%) | 59 (28.4) | |
Pack years (median [IQR]) | 13.8 [0.0, 28.0] | |
Hypercholesterolemia (%) | 56 (26.9) | |
Hypertension (%) | 40 (19.2) | |
Diabetes Mellitus (%) | 9 (4.3) | |
No cardiovascular risk factors (%) | 50 (24.0) | |
Statins (%) | 56 (26.9) | |
Aspirin (%) | 18 (8.7) | |
Metformin (%) | 9 (4.3) | |
